Lil­ly diss­es Am­gen and Mi­rati as it de­buts new KRAS mol­e­cule

Eli Lil­ly is re­join­ing the KRAS hunt.

The In­di­anapo­lis Big Phar­ma re­vealed Thurs­day, in an ab­stract for AACR, that it has been work­ing on a new small mol­e­cule to tar­get the in­fa­mous onco­gene and are plan­ning to put it in­to Phase I lat­er this year. It marks Lil­ly’s first pub­lic for­ay in­to the field in near­ly a year, since it ditched its first mol­e­cule af­ter see­ing dan­ger­ous side ef­fects in five pa­tients.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER